FDA Approves Ferumoxytol as Novel Brain Cancer Imaging Agent After 30 Years of OHSU Research
核心洞察
The FDA has approved ferumoxytol (FERABRIGHT (搜索)™), an iron-based anemia drug, as a contrast agent for brain cancer imaging after nearly three decades of research at Oregon Health & Science University.
The approval provides physicians with a multidimensional imaging tool that can measure tumor blood volume and track immune cells, offering superior visualization compared to traditional gadolinium-based contrast agents.
OHSU partnered with Azurity Pharmaceuticals (搜索) to conduct phase 3 re-read studies using clinical trial data from nearly two decades to achieve FDA approval through a New Drug Application process.
The Food and Drug Administration has approved ferumoxytol, marketed as FERABRIGHT (搜索)™, as a contrast agent for brain cancer imaging, marking the culmination of nearly 30 years of research at Oregon Health & Science University. The iron-based substance, previously used primarily to treat anemia, now offers physicians a new tool to detect and monitor tumor progression in brain cancer patients.
The groundbreaking research began in an OHSU laboratory three decades ago under the leadership of Edward Neuwelt, M.D., a professor in OHSU's Department of Neurology and founder of the university's Neuro-Oncology Blood-Brain Barrier Program. The successful completion of this decades-long project provides physicians with an additional, multidimensional view of cancerous areas in the brain.
"Our hope as researchers is that the work we do in the lab can enable real-world advancements in clinical capabilities," said Lisa Muir, M.P.A: HA, senior research project manager in the Neuro-Oncology Blood-Brain Barrier Program. "This work — which has been decades in the making — will impact treatment for countless patients battling brain cancer."
Superior Imaging Capabilities
Magnetic resonance imaging serves as the primary clinical tool for visualizing the tumor environment around a patient's cancer. While traditional diagnostic technology has relied on gadolinium-based contrast agents that cause tumor areas to light up on MRI scans, these agents provide only a limited, one-dimensional view of the tumor environment, showing location without biological information.
Ferumoxytol-enhanced MRI offers significant advantages over conventional imaging approaches. Researchers found that using ferumoxytol allows clinicians to measure blood volume in tumors, an important indicator of cancer growth, as well as track immune cells and visualize inflammation. Across clinical trials, ferumoxytol-enhanced MRI demonstrated significantly improved visualization of both primary and secondary brain tumors compared with pre-contrast imaging.
"With all brain cancers, but especially glioblastoma, the fastest growing and most aggressive form of brain cancer, it's crucial we approach treatment with as much efficiency and precision as possible," said Ramon Barajas, Jr., M.D., professor of diagnostic radiology in the OHSU School of Medicine. "The FDA approval of ferumoxytol for imaging is an incredibly exciting advancement for the field of neuro-oncology because it offers a new approach to imaging assessment, which may ultimately lead to prolonging life and improving quality of life for our patients."
Rigorous Development Process
The path to FDA approval required extensive clinical validation. Neuwelt began preclinical laboratory studies on ferumoxytol-enhanced MRI three decades ago, which eventually translated into several OHSU clinical trials. OHSU partnered with Azurity Pharmaceuticals (搜索) to conduct a comprehensive series of independent, blinded, phase 3 re-read studies utilizing images, data, and clinical information from OHSU patients who participated in clinical trials over nearly two decades.
The FDA approval process involved a New Drug Application (NDA) that Neuwelt initiated in 2011. Over the last five years, a core team of researchers in Neuwelt's group — including Muir, Amy Huddleston, M.P.A: HA, Leslie Muldoon, Ph.D., Rochelle Fu, Ph.D., and Laszlo Szidonya, M.D., Ph.D. — worked to complete the project by designing three new studies based on existing OHSU clinical trial data, collecting and analyzing data in response to FDA requirements, and providing documentation throughout the FDA inspection and review process.
Clinical Impact and Future Directions
The approval addresses a critical need in brain cancer care, where patients often struggle to understand tumor progression and appropriate treatment options. "Patients with brain cancer are often left feeling frustrated trying to understand their tumor's progression and what the right treatment is," Barajas noted. "Now with a new path forward, we hope patients are provided some hope and comfort in this extremely difficult moment."
"OHSU is the birthplace of many innovative new ideas, but it's not easy bridging the gap between promising research and real-world applications," said Travis Cook, M.S., M.B.A., senior director of OHSU Technology Transfer. "It's not every day a research discovery makes it out of the lab, and further, has the potential to impact treatment decisions and disease outcomes for patients."
The research team plans to continue exploring various uses and potential impacts of ferumoxytol in combination with other contrast agents and imaging techniques, including PET/MRI and hypoxia imaging, potentially expanding the clinical applications of this breakthrough technology.